With direct letters, regulatory comments and other activities, Vizient strives to form constructive relationships with lawmakers, regulatory agencies and administration officials, to provide a unified voice on issues that have a direct impact on our members.
2026 Advocacy
- January 26 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program
- January 6 - Vizient comments to the Partnership for Quality Management (P4QM) on the 2025 Measures Under Consideration (MUC) List
- January 6 - Vizient comments to the Food and Drug Administration (FDA) on draft guidance for industry, “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies”
Connect with Vizient to help you solve health care’s biggest challenges